The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. - Wikidata - thesis-toulmin - TriplyDB

The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial.

The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial.

http://www.wikidata.org/entity/Q35898610

about

Interventions for preventing neuropathy caused by cisplatin and related compounds Neuropathic cancer pain: What we are dealing with? How to manage it?Chemotherapy-induced peripheral neurotoxicity: a critical analysis Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review Chemotherapy-induced neuropathies-a growing problem for patients and health care providers Lifestyle-Related Factors in the Self-Management of Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer: A Systematic Review.Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study Efficacy of Drug Interventions for Chemotherapy-Induced Chronic Peripheral Neurotoxicity: A Network Meta-analysis Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience.Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging.Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer.Platinum-induced neurotoxicity and preventive strategies: past, present, and future Influence of dosing times on cisplatin-induced peripheral neuropathy in rats.New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.Effect of Vitamin E on Oxaliplatin-induced Peripheral Neuropathy Prevention: A Randomized Controlled Trial.Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.Neurological Adverse Effects in Patients of Advanced Colorectal Carcinoma Treated with Different Schedules of FOLFOX Clinical study on the prevention of oxaliplatin-induced neurotoxicity with guilongtongluofang: results of a randomized, double-blind, placebo-controlled trial.National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons.The search for treatments to reduce chemotherapy-induced peripheral neuropathy.Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy.Inhibition of cancer antioxidant defense by natural compounds.Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: creating a doctor-patient dialogue.Brief review: chemotherapy-induced painful peripheral neuropathy (CIPPN): current status and future directions.Occupational exposure to municipal solid wastes and development of toxic neuropathies: possible role of nutrient supplementation, complementary and alternative medicines in chemoprevention.Chemotherapy-induced peripheral neurotoxicity (CIPN): what we need and what we know.Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.Efficacy and Interaction of Antioxidant Supplements as Adjuvant Therapy in Cancer Treatment: A Systematic Review.Dietary Supplements Commonly Used by Cancer Survivors: Are There Any Benefits?Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy.Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.Chemotherapy-induced peripheral neuropathy: limitations in current prophylactic strategies and directions for future research.Vitamin E does not decrease the incidence of chemotherapy-induced peripheral neuropathy: a meta-analysis.BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study.Paclitaxel alters the evoked release of calcitonin gene-related peptide from rat sensory neurons in culture.Preventive Effects of Bee Venom Derived Phospholipase A₂ on Oxaliplatin-Induced Neuropathic Pain in Mice.Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: a pilot randomized clinical trial.

P2860

Q24197763-E332D267-691F-4CD4-BCCB-4918849684A9 Q26998945-5C8CB051-6630-4056-B7AB-227135C0E3D6 Q27010318-44BAE041-B63D-40B0-880C-73745AD786B4 Q28270819-6EF9617D-0912-4368-88EC-8D6A377CB34E Q28818565-A950479D-C215-4105-ABDE-0227FB75FDB1 Q30234847-2FB4DF3D-956B-4B28-A1A8-17354E6E6B89 Q33561260-AE56C4E4-586D-4439-BB20-13AE5D897446 Q33717608-706F1CF7-2C1F-472D-A9FA-0414DB9988BF Q33774892-4AA6DD49-8C4D-48AB-8E30-091890A4FC40 Q33984071-7DB613CB-D042-4C1D-8E42-804BC014CEF1 Q34430049-B23FE6B6-261C-491A-B0A4-9D4B4D1E197E Q34458581-FFBFDC0A-C14E-442F-B1BD-489EA5D37EDC Q35345734-9FD53790-0A73-43E5-90EC-1EA9AD96DF26 Q36146524-6616CD51-557C-4FD6-B6B5-DEF748F95827 Q36226275-F645A976-CCC6-439A-9A7C-5A6C3795B29E Q36350645-5328C31A-DFEC-47BA-AF0B-33DD4538F9C0 Q36977059-2E4698DD-941C-4672-BDF7-A8C58B2CBB24 Q37031281-1F24061C-0C31-49EB-A6C9-0CE610F4B95C Q37233810-38EB72DC-229B-4FEF-93FE-A42D48C79B8E Q37244795-D8BBDCBE-B5BE-4702-8A1C-9B3424EBB03D Q37353630-8CACA618-C170-4E52-B242-1B6C4DD6C44E Q37364316-74A4B45F-C2D3-4127-B673-120F61AC9B65 Q37410650-8E047F5B-607E-4803-BA6E-A00462D9A516 Q37541146-C0C0C20C-382C-4B34-A51F-29CE51D8D6CB Q37716657-EE8E5EF8-D385-461E-A017-DAF3970D2624 Q38197147-04A6EF53-5764-44AA-95DC-28B73AC86DB4 Q38209959-089FCFFE-6D38-4A1F-A53A-A914A77B3012 Q38217325-2C52AFA5-9B9E-41D1-B103-A4EBBA8B797C Q38224422-BD54C502-7D87-402B-8CA2-C5E20F0D7D46 Q38264622-55885D35-A626-4A62-BB06-2A1C585649F6 Q38616751-8E4B8B75-CC9E-4447-BFDB-9F86F4664138 Q38622264-EF82DF34-26D9-4FF1-B2C4-974E2D737F65 Q38637751-FD71F967-5ACE-44EE-A2E3-36CC742A6BF3 Q38716340-29F1CC4F-7847-49C9-AFC9-ACFA4E179F99 Q38769139-05F1ED61-7D72-4E6C-81CD-4A60C1B2A295 Q38959385-7CBD4F0C-7496-4B3A-B605-5C703E6B75CF Q39236303-D5F4B9D2-6787-4B9D-945D-A3D3109999F5 Q39283600-810D6E1A-47F2-4957-A8D2-1D0437AEFA2C Q43066432-CFDBF23D-D6EB-4D7D-8D2A-8E7A55E19C6B Q44117079-3D4E2A7C-8FD6-41E7-856C-9446A573CB92

P2860

The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial.

http://www.wikidata.org/entity/Q35898610

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

The use of vitamin E for the p ...... ized phase III clinical trial.

@ast

The use of vitamin E for the p ...... ized phase III clinical trial.

@en

type

label

The use of vitamin E for the p ...... ized phase III clinical trial.

@ast

The use of vitamin E for the p ...... ized phase III clinical trial.

@en

prefLabel

The use of vitamin E for the p ...... ized phase III clinical trial.

@ast

The use of vitamin E for the p ...... ized phase III clinical trial.

@en

P1433

Q35898610-B06EEE01-636B-4FB0-AAF2-22ABCB4BA768

P1476

Q35898610-BC8E4A5B-E33D-4B9D-90CC-105DE762FEEC

P2093

Q35898610-360405DE-DA73-42F8-8EEA-185C9199E1F8

Q35898610-45506B1A-050A-48A8-A180-C7BE59E9FB47

Q35898610-4F4269D8-DD1B-440B-94D0-A26C651D3EFC

Q35898610-6897D4D1-B44E-41EA-9BAD-50ABA91C42EC

Q35898610-772A46FE-F53E-441D-8F7D-38CCFC5D66A8

Q35898610-7BFD067E-944F-4105-B4F9-3EAC92025CCB

Q35898610-918E4A30-DAF5-468B-B7C7-452764437F48

Q35898610-CC6DF850-BD9E-4DD3-99F7-59F0D757EB28

Q35898610-D8BA6FB5-071A-47B3-A416-4028698B4E56

Q35898610-FCFBB4B8-BB70-4B78-B973-5CF04641A5B5

P2860

Q35898610-0F6947AE-61A4-4E07-B79E-74DD45319FDC

Q35898610-150ADDDC-74E8-41C4-A6EC-AED04967EC05

Q35898610-210E1D0C-DC2F-475B-9C1A-FA829237D74E

Q35898610-2651471F-AF1A-48F7-94B5-13150A7FB7CF

Q35898610-33A72265-F1EE-4764-86DC-ECF602826495

Q35898610-51604CA2-89B7-4DE0-991A-3B888548D1D8

Q35898610-5389106B-6C8F-4525-B3FF-F5284B118324

Q35898610-5F679A91-6426-4D8A-9B17-4DFB73B1F336

Q35898610-677258D2-23F5-4180-A8C6-12A37A8D23BD

Q35898610-6F24E035-99BD-4D81-9B98-1C2E1D6044C4

P2888

Q35898610-0419191F-39DE-4269-BDD0-F24427B7058B

P304

Q35898610-B5870516-EEB7-41FA-8DDF-5B4A4B820247

P31

Q35898610-9C490F1B-5DE1-4206-94CF-8984B608170A

P356

Q35898610-8ADA8361-9B98-46C0-9C4E-20AEA0490AE9

P433

Q35898610-4E47F09D-72F9-409C-A5A9-5C40A7B403C6

P478

Q35898610-82183182-8DD4-482A-A17F-0B834FF22E67

P577

Q35898610-9239EE1A-109C-4665-9A58-6FA2DC187F75

P5875

Q35898610-D3BCBD10-CAA6-4374-90C0-6E5D28387606

P698

Q35898610-B4F62B15-BA2E-4E93-9427-DF2B03AFF582

P921

Q35898610-4F89A148-51A3-41E9-9224-9D8F0EC50457

Q35898610-91CDDCCF-6C91-4D5E-A9EC-243502DE7411

P932

Q35898610-E6060507-DDF3-40E6-B8AF-1AC00AD3A888

P356

S00520-010-1018-3

P1433

Supportive Care in Cancer

P1476

The use of vitamin E for the p ...... ized phase III clinical trial.

@en

P2093

Alan R Berg

http://www.w3.org/2001/XMLSchema#string

Bronagh P Murphy

http://www.w3.org/2001/XMLSchema#string

Charles L Loprinzi

http://www.w3.org/2001/XMLSchema#string

David B Johnson

http://www.w3.org/2001/XMLSchema#string

Deanne A Smith

http://www.w3.org/2001/XMLSchema#string

Jeff A Sloan

http://www.w3.org/2001/XMLSchema#string

Kendrith M Rowland

http://www.w3.org/2001/XMLSchema#string

Lisa A Kottschade

http://www.w3.org/2001/XMLSchema#string

Miroslaw A Mazurczak

http://www.w3.org/2001/XMLSchema#string

Philip J Stella

http://www.w3.org/2001/XMLSchema#string

P2860

Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials.

Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine.

Management of painful diabetic neuropathy.

Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy.

Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).

Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms.

Management strategies for the treatment of neuropathic pain in the elderly.

Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.

Long-term complications of chemotherapy for germ cell tumours.

Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies.

P2888

s00520-010-1018-3

P304

1769-1777

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-010-1018-3

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47385556

http://www.w3.org/2001/XMLSchema#string

P698

20936417

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

3329941

http://www.w3.org/2001/XMLSchema#string